Skip to main content
  • More from ADA
    • Diabetes
    • Diabetes Care
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Clinical Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
  • Browse
    • Issue Archive
    • Saved Searches
    • COVID-19 Article Collection
    • Quality Improvement Sucess Stories
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
    • Clinical Compendia
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
  • Advertising
  • Reprints/Reuse
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • Instructions for Authors
    • ADA Journal Policies
  • More from ADA
    • Diabetes
    • Diabetes Care
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
  • Browse
    • Issue Archive
    • Saved Searches
    • COVID-19 Article Collection
    • Quality Improvement Sucess Stories
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
    • Clinical Compendia
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
  • Advertising
  • Reprints/Reuse
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • Instructions for Authors
    • ADA Journal Policies
Feature Articles

Diabetic Myonecrosis: An Indian Experience

  1. Dayanidhi Meher, MD, DM,
  2. Vivek Mathew, MD, DM,
  3. Raiz Ahmed Misgar, MD, DM,
  4. Satinath Mukherjee, MD, DM,
  5. Subhankar Chowdhury, DM, MRCP and
  6. Jyothi Chowdhury, MBBS, DTM&H
Clinical Diabetes 2013 Apr; 31(2): 53-58. https://doi.org/10.2337/diaclin.31.2.53
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

IN BRIEF

Diabetic myonecrosis is an uncommon muscular complication of diabetes with significant morbidity. Clinical features and radiological findings are helpful in the diagnosis of myonecrosis. Management is conservative and focused on symptomatic relief and control of diabetes.

Diabetic myonecrosis is an under-recognized and under-reported complication of longstanding diabetes. In this case series, we have attempted to report the clinical and radiological characteristics of six patients with diabetic myonecrosis along with a review of existing literature.

Case Report 1

A 53-year-old woman presented with painful swelling of the right thigh that had been present for the past 9 days. The pain was of acute onset, dullaching, and constant and was sufficient to make her nonambulatory. There was no history of trauma or fever. She had been diagnosed with type 2 diabetes 1 year ago and hypertension 5 years ago.

On examination, her right thigh was swollen with a diffuse, indurated tender mass over the anterolateral aspect (Figure 1). The margins were not distinct, and there were no other signs of inflammation or pus formation. She was afebrile. A vibration perception test revealed moderate peripheral neuropathy. There was no evidence of nephropathy or retinopathy.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Case report 1: right thigh showing diffuse swelling (white arrow) anterolaterally.

Laboratory investigations revealed poor glycemic control (fasting plasma glucose [FPG] 327 mg/dl, postprandial plasma glucose [PPG] 417 mg/dl) and dyslipidemia (total cholesterol 206 mg/dl, triglycerides 156 mg/dl, LDL cholesterol 141 mg/dl, and HDL cholesterol 34 mg/dl). Her serum creatine kinase (CK) was 311 U/l (normal < 167 U/l), and her serum lactic dehydrogenase (LDH) was 394 U/l (normal 240–480 U/l). Total leukocyte and differential counts were normal. Lupus anticoagulant and antiphospholipid antibodies were negative.

Ultrasonography showed an ill-defined hypoechoeic area measuring 25 × 15 cm2 over the lateral aspect of the right mid-thigh. Magnetic resonance imaging (MRI; T2-weighted short TI inversion recovery images) showed heterogenous and hyperintense areas involving the anterior and medial group of right thigh muscles mainly in its lower half. A post-gadolinium contrast study showed mild enhancement, and there was no area of pus collection. Adjacent subcutaneous tissue was edematous. A muscle biopsy revealed infiltration of lymphocytes and plasma cells. There was evidence of degeneration and necrosis in the muscle fibers (Figure 2).

She was managed with bed rest, analgesics, and optimal glycemic control. The pain and swelling resolved completely within 4 weeks. She came to us again 2 years later with recurrence of myonecrosis on the opposite thigh (Figure 3).

Case Report 2

A 37-year-old woman with type 2 diabetes for 8 years presented to us with painful swelling of the left thigh for the past week. She was afebrile, and there was no history of local trauma. There was no weakness in the left thigh, but movement was restricted because of severe pain. She had received antibiotics, which did not relieve her symptoms.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Case report 1: muscle biopsy of right thigh showing infiltration of inflammatory cells with muscle fiber degeneration (white arrow).

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Case report 1: swollen left thigh (white arrow) with scar on right thigh (black arrow) from previous biopsy.

Her glycemic control was poor (FPG 289 mg/dl, PPG 389 mg/dl, A1C 9.2%). Other laboratory findings revealed a hemoglobin level of 10.2 g/dl, erythrocyte sedimentation rate (ESR) of 32 mm/hour, serum creatinine of 2.1 mg/dl, total cholesterol of 211 mg/dl, LDL cholesterol of 112 mg/dl, and triglyceride level of 287 mg/dl. There was no evidence of systemic inflammation, and muscle enzymes (CK and LDH) were normal.

She had microvascular complications in the form of diabetic nephropathy (chronic kidney disease [CKD] stage 3), bilateral severe nonproliferative diabetic retinopathy (NPDR), and distal symmetrical polyneuropathy (DSPN). Ultrasonography showed a diffuse hypoechoic area covering the anterolateral aspect of the left thigh. MRI revealed features suggestive of muscle inflammation.

She was managed with bed rest, analgesics, and optimal glycemic control and recovered in a period of 6 weeks.

Case Report 3

A 53-year-old woman with type 2 diabetes for 5 years presented with pain in her right thigh of 5 days' duration. The pain was abrupt and spontaneous and had curtailed her day-to-day activities. The right thigh was swollen uniformly and was tender.

She had microalbuminuria, bilateral NPDR with clinically significant macular edema, and DSPN. She had a history of foot ulcer.

Laboratory investigation revealed poor glycemic control, leukocytosis, elevated ESR, and dyslipidemia. Serum CK and LDH levels were within normal limits. Serum antinuclear antibody, rheumatoid factor, and antiphospholipid antibodies were not detected.

Ultrasonography showed hypoechoic areas in the muscle and minimal fluid collection in the intermuscular spaces. Culture of the aspirated fluid was sterile. MRI was suggestive of diabetic myonecrosis.

The patient was managed with bed rest, analgesics, and optimal glycemic control and recovered in a period of 4 weeks.

Case Report 4

A 55-year-old man with type 2 diabetes for 12 years and poor glycemic control presented with bilateral painful thigh swelling of 4 days' duration. The swelling was asymmetrical and more prominent on the left side.

He had micro- and macrovascular complications in the form of nephropathy, DSPN, bilateral mild NPDR, and coronary heart disease.

Laboratory investigations did not reveal any evidence of inflammation. Serum CK and LDH levels were within normal limits.

Venous Doppler of the lower limbs was normal. Ultrasonography showed a diffuse hypoechoic area in the quadriceps muscles bilaterally. Because he could not afford an MRI study, a bilateral muscle biopsy was performed and revealed degeneration and necrosis of muscle fibers.

He was managed with bed rest, analgesics, and optimal glycemic control and recovered in a period of 4 weeks.

Case Report 5

A 55-year-old man with type 2 diabetes for 10 years presented with painful swelling of the right thigh for the past 2 days. His evaluation revealed microvascular complications in the form of bilateral NPDR and DSPN. There was no evidence of nephropathy.

MRI and ultrasonography of the right thigh was suggestive of myonecrosis.

He was managed with bed rest, analgesics, and optimal glycemic control and recovered in a period of 4 weeks.

Case Report 6

A 56-year-old woman with type 2 diabetes for 25 years presented with rapid-onset spontaneous painful swelling of the right thigh and leg for 2 weeks. On examination, there was a diffuse swelling over the right thigh and leg.

She was on insulin and anti-hypertensive drugs. Her glycemic control was poor (FPG 292 mg/dl, PPG 401 mg/dl, A1C 10.2%). She had microvascular complications in the form of diabetic nephropathy (CKD stage 3) and DSPN.

Fundus examination was normal. Total leucocyte count, ESR, and muscle enzymes (CK and LDH) were normal. MRI (Figure 4) and ultrasonography revealed features suggestive of myonecrosis involving the right thigh and leg. She was managed with bed rest, analgesics, and optimal glycemic control and recovered in a period of 3 weeks.

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

Case report 6: T2 MRI (fat suppressed) of both thighs with right thigh showing increased signal intensity over quadriceps muscles.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 1.

Characteristics of Our Patients With Diabetic Myonecrosis

Table 1 presents a summary of the patients in these six case reports.

Overview of Myonecrosis

Diabetic myonecrosis is a complication of longstanding diabetes. Since its first description by Angervall and Stener in 1965,1 ~ 100 cases have been reported in the literature.2 Diabetic myonecrosis is also known as spontaneous diabetic muscle infarction (DMI), aseptic myonecrosis, ischemic myonecrosis, and tumoriform focal muscular degeneration.

Diabetic myonecrosis is rare, and there is a relative lack of awareness about it compared to other complications of diabetes. Hence, there is often a delay in diagnosis, which in turn increases the morbidity associated with the disease.3 Women with longstanding type 1 diabetes are the most common patients to develop this disease. In patients with type 2 diabetes, older individuals are more commonly affected.4,5 Diabetic myonecrosis is usually seen in patients with longstanding diabetes who are on insulin therapy and have multiple micro- and macrovascular complications.4–6

The diagnosis criteria for diabetic myonecrosis are summarized in Table 2 and discussed in detail below.

Clinical presentation

Clinical presentation of myonecrosis typically includes an abrupt onset of diffuse painful swelling of involved muscles and occasionally a palpable mass without antecedent trauma or infection. Bilateral involvement is seen in 8–10% of cases.4,5 An increase in the dimensions of the thigh may be the initial presenting feature. Fever and other signs of inflammation are usually absent.

Thigh muscles are commonly affected, with the quadriceps being the most frequently involved muscle group.7 Vastus lateralis and vastus medialis are the most commonly affected muscle sites.8 Involvement of calf and upper-extremity muscle groups has also been documented.4,8,9 With time, the swelling localizes, and the predominant symptom may be pain with restriction of movement.10

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 2.

Criteria for Diagnosis of Diabetic Myonecrosis

Pathophysiology of myonecrosis

Possible pathological mechanisms revolve around diabetic microangiopathy, vasculitis with thrombosis, hypoxia-reperfusion injury, and atherosclerotic occlusion.11,12 Patients generally have end-organ complications of diabetes, suggesting the role of small vessel disease and atherosclerosis as an underlying pathology.

Cases of diabetic myonecrosis also have been reported with cirrhosis and antiphospholipid antibody syndrome. Diabetes is a proinflammatory state, with increased activity of factor VII, plasminogen activator inhibitor-1, and thrombomodulin. This in turn creates a hypercoagulable state.5,13,14 The coagulation abnormalities associated with cirrhosis may put patients at risk for hematoma formation and infection. Ischemia and associated edema may aggravate the local pressure effect, which may further compromise blood flow to the affected muscles.15 Hence, ischemia and edema may form a vicious circle leading to worsening of diabetic myonecrosis.

Galtier-Dereure et al.16 have shown a high prevalence of antiphospholipid antibodies in patients with type 1 or type 2 diabetes and end-organ complications. The coexistence of diabetes and antiphospholipid antibodies increases hypercoagulability and puts patients at high risk for thrombotic complications and diabetic myonecrosis. Vasculitis with fibrinoid necrosis, although reported in diabetic myonecrosis, is rare.17

Laboratory investigations and radiology

Laboratory evaluation shows an elevated ESR in half of the cases.4 Leucocytosis is generally absent. Serum levels of muscle enzymes such as CPK and LDH are usually normal or mildly elevated.8 Serum levels of aspartate and alanine transaminases are generally normal.

Bedside ultrasonography is the first-line imaging diagnostic modality in diabetic myonecrosis. Ultrasonography generally reveals a well-marginated, hypoechoic, intramuscular lesion with the following additional features: internal linear structures that suggest muscle fibers coursing through the lesion, lack of a predominately anechoic region, and absence of motion or swirling of fluid with transducer pressure.18 The advantages of ultrasonography include easy availability, noninvasiveness, early diagnosis, and exclusion of other causes such as soft-tissue abscess.

Imaging studies may be quite useful in the diagnosis of diabetic myonecrosis and can simultaneously exclude other differential diagnoses such as cellulitis, abscess, fracture, tropical pyomyositis, necrotizing fasciitis, diabetic lumbar plexopathy, and deep vein thrombosis.

MRI studies show increased signal intensity from the affected muscle area in T2-weighted, inversion recovery, and gadolinium-enhanced images and isointense or hypointense areas on T1-weighted images. The pathological basis of these findings is the presence of increased water content resulting from edema.19 Other findings include diffuse enlargement of affected muscles, ill-defined borders secondary to loss of the normal fatty intramuscular septa, and hemorrhagic foci.20 The disadvantages of MRI include its high cost, lack of universal availability, and nonspecificity. Many MRI findings seen in diabetic myonecrosis can also be found in other inflammatory myopathies. Computed tomography (CT) scans show diffuse muscular enlargement with diminished attenuation of the affected muscle, increased attenuation of the subcutaneous fat, and thickening of subcutaneous fascial planes and skin.21

Because MRI and CT scans are nonspecific, many patients also are subjected to biopsy. Findings on muscle biopsy depend on the stage of the myonecrosis. Early on, light microscopy shows large areas of muscle necrosis and edema, phagocytosis of the necrotic muscle fibers, and variable presence of granular tissue and collagen. At a later stage, there is a fibrous replacement of the necrotic tissue, myofiber regeneration, and mononuclear cell infiltration.22 Small vessel walls are often hyalinized and thickened with evidence of atherosclerosis. Some small vessels may be occluded with fibrin or calcium fragments.

Conflicting reports suggest that biopsy may be associated with hematoma formation, infection, and an extended recovery period.15,17,23 Cultures for bacteria and fungi are generally negative unless there is a complicated myonecrosis.6 However, because biopsy is invasive and noninvasive investigations such as ultrasound are easily available, biopsy should be reserved for cases in which the clinical presentation is atypical or the diagnosis uncertain or when appropriate treatment fails to elicit clinical improvement.15,19,24

Differential diagnosis

Other conditions that may mimic myonecrosis include soft-tissue abscess, necrotizing fasciitis, pyomyositis, dermatomyositis, benign muscle tumors, lymphomas, sarcomas, diabetic amyotrophy, drug-induced myositis, osteomyelitis, muscle rupture, hematoma, ruptured Baker's cyst, deep-vein thrombosis, diabetic lumbosacral plexopathy, and thrombophlebitis. Clinical presentation, laboratory investigations, MRI, and sonographic features, along with the course of the disease, all help in differentiation. Soft-tissue abscesses on ultrasound are anechoic or hypoechoic, well defined, and show posterior acoustic enhancing and intrinsic motion of fluid. Patients with pyomyositis generally will have systemic symptoms with fever and leucocytois. ESR, CPK, and LDH are generally elevated. Blood cultures and local tissue cultures may grow Staphylococcus aureus. Venous Doppler studies may be required to rule out deep-vein thrombosis.

Treatment and prognosis

Treatment for diabetic myonecrosis is generally conservative and supportive. Bed rest is usually advised, although there are conflicting reports on the benefits of physical therapy.8,12,15 Nonsteroidal anti-inflammatory drugs and narcotics may be used for inflammation and pain control. Good glycemic control during the hospital stay is recommended. Anticoagulants may be used only if a patient has a hypercoagulable state such as antiphospholipid syndrome. In general, surgical interventions should be avoided unless there is a complicated diabetic myonecrosis with abscess formation or peripheral arterial compromise.14

Generally, the short-term prognosis is good for diabetic myonecrosis. The swelling and pain lessen, and patients become mobile in 1–2 months. However, patients usually have associated micro- and macrovascular complications that affect the long-term prognosis and elevate 5-year mortality.3,4 Patients are known to have recurrences, and most events occur within a period of 2 months after the initial presentation.

Experience with diabetic myonecrosis

Diabetic myonecrosis has been more frequently reported in women. Four (66.6%) of the patients in our series described above were women. The mean age at presentation was 51.5 ± 7.2 years (range 37–56 years), which is higher than noted in a previously published review.5 The fact that all of our patients had type 2 diabetes may have contributed to the higher mean age.

The mean duration of diabetes, from initial diagnosis to the first episode of myonecrosis, was 10.16 ± 8.23 years (range 1–25 years). Our patients had multiple end-organ diabetes complications. All of our patients had neuropathy and diabetic dyslipidemia. Nephropathy was present in five cases, and retinopathy was present in four cases.

All of our patients presented with typical clinical features of diabetic myonecrosis such as abrupt onset of pain and swelling in the affected muscles. Fever has been reported in ~ 10% of patients with diabetic myonecrosis, but none of our patients had a fever.

Diabetic myonecrosis has a predilection for thigh muscles. In our series, all six patients had involvement of the quadriceps, and one patient (case report 6) had involvement of calf muscles in addition to the quadriceps. One of our patients had bilateral involvement (case report 4). In the literature, bilateral involvement was reported in 8–10% of cases.

Plasma levels of muscle enzymes were elevated in only one of our patients (case report 1). Leucocytosis and elevated ESR were reported in ~ 8 and 52% of patients, respectively. We noted leucocytosis in case report 3 and elevated ESR in case reports 2 and 3.

We managed our patients with bed rest and analgesics. Glycemic control was optimized. All of our patients had complete resolution of myonecrosis without any complications in 4.16 ± 0.96 weeks.

In diabetic myonecrosis, recurrence was reported in ~ 47% of patients. The majority (81%) of these patients have recurrences in a different muscle. In our series, one patient (case report 1) had recurrence of myonecrosis in the opposite thigh 2 years after the first presentation.

Conclusion

Diabetic myonecrosis is an uncommon complication of longstanding diabetes. Patients may present with pain and swelling of involved muscle groups, leading to significant morbidity. Management is conservative, with good short-term prognosis. The long-term prognosis of these patients is poor, in part because many of them already have micro- and macrovascular complications of diabetes.

Footnotes

  • Dayanidhi Meher, MD, DM, is a postdoctoral trainee; Satinath Mukherjee, MD, DM, is a professor; and Subhankar Chowdhury, DM, MRCP, is a professor and head of the Department of Endocrinology and Metabolism at the Institute of Post-Graduate Medical Education and Research in Kolkata, India. Raiz Ahmed Misgar, MD, DM, is a consultant in endocrinology in Kashmir, India. Vivek Mathew, MD, DM, is an assistant professor in the Department of Endocrinology at St. Johns Medical College in Bangalore, Karnataka, India. Jyothi Chowdhury, MBBS, DTM&H, is a consultant pathologist at the Nightingale Diagnostic & Medicare Center in Shakespeare Sarani, Kolkata, West Bengal.

  • American Diabetes Association(R) Inc., 2013

REFERENCES

  1. ↵
    1. Angervall L,
    2. Stener B
    : Tumoriform focal muscular degeneration in two diabetic patients. Diabetologia 1:39–42, 1965
    OpenUrlCrossRef
  2. ↵
    1. Maclsaac RJ,
    2. Jerums G,
    3. Scurrah L
    : Diabetic muscle infarction. Med J Aust 177:323–324, 2002
    OpenUrlPubMedWeb of Science
  3. ↵
    1. Wintz RL,
    2. Pimstone KR,
    3. Nelson SD
    : Detection of diabetic myonecrosis: complication is often-missed sign of underlying disease. Postgrad Med 119:66–69, 2006
    OpenUrlPubMed
  4. ↵
    1. Trujillo-Santos AJ
    : Diabetic muscle infarction: an underdiagnosed complication of long-standing diabetes. Diabetes Care 26:211–215, 2003
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Mancillas-Adame LG,
    2. González-González JG,
    3. Jáquez-Quintana JO,
    4. Cardoza-Torres MA,
    5. García Ade L
    : Diabetic myonecrosis in a patient with hepatic cirrhosis: a case report and review of the literature. J Med Case Rep 3:9305, 2009
    OpenUrlCrossRefPubMed
  6. ↵
    1. Rajiv R,
    2. Davidson MB
    : Diabetic muscle infarction: a rare complication of diabetes mellitus. Endocrinologist 14:167–170, 2004
    OpenUrlCrossRef
  7. ↵
    1. Chow KM,
    2. Szeto CC,
    3. Wong TY,
    4. Leung FK,
    5. Cheuk A,
    6. Li PK
    : Diabetic muscle infarction (Letter). Diabetes Care 25:1895, 2002
    OpenUrlFREE Full Text
  8. ↵
    1. Bunch TJ,
    2. Birskovich LM,
    3. Eiken PW
    : Diabetic myonecrosis in a previously healthy woman and review of a 25-year Mayo Clinic experience. Endocr Pract 8:343–346, 2002
    OpenUrlPubMed
  9. ↵
    1. Mukhopadhyay P,
    2. Barai R,
    3. Philips CA,
    4. Ghosh J,
    5. Saha S
    : An unusual case of myonecrosis. Case Rep Endocrinol Article ID 624020, 2011 (doi:10.1155/2011/624020)
  10. ↵
    1. Umpiérrez GE,
    2. Stiles RG,
    3. Kleinbart J,
    4. Krendel DA,
    5. Watts NB
    : Diabetic muscle infarction. Am J Med 101:245–250, 1996
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. Scully RE,
    2. Mark EJ,
    3. McNelly WF,
    4. Ebeling SH,
    5. Phillips LD
    : Case 29–1997: case records of the Massachusetts General Hospital. N Engl J Med 337:839–845, 1997
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    1. Habib G,
    2. Nashashibi M,
    3. Walid S
    : Diabetic muscular infarction: emphasis on pathogenesis. Clin Rheumatol 22:450–451, 2003
    OpenUrlCrossRefPubMed
  13. ↵
    1. Palmer GW,
    2. Greco TP
    : Diabetic thigh muscle infarction in association with antiphospholipid antibodies. Semin Arthritis Rheum 30:272–280, 2001
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    1. Bjornskov EK,
    2. Carry MR,
    3. Katz FH,
    4. Leflowitz J,
    5. Ringel SP
    : Diabetic muscle infarction: a new perspective on pathogenesis an management. Neuromusc Disord 5:39–45, 1995
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    1. Chester CS,
    2. Banker BQ
    : Focal infarction of muscle in diabetics. Diabetes Care 9:623–630, 1986
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Galtier-Dereure F,
    2. Biron C,
    3. Vies M,
    4. Bourgeois V,
    5. Schved JF,
    6. Bringer J
    : Vascular complications of diabetes mellitus: what role for phospholipid-binding antibodies? Lupus 7:469–470, 1998
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Chason DP,
    2. Fleckenstein JL,
    3. Burns DK,
    4. Rojas G
    : Diabetic muscle infarction: radiologic evaluation. Skeletal Radiol 25:127–132, 1996
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    1. Nagdev A,
    2. Murphy M,
    3. Sisson C
    : Bedside ultrasound for the detection of diabetic myonecrosis. Am J Emerg Med 26:969.e3–969.e4, 2008
    OpenUrlCrossRefPubMed
  19. ↵
    1. Sharma P,
    2. Mangwana S,
    3. Kapoor RK
    : Diabetic muscle infarction: atypical MR appearance. Skeletal Radiol 29:477–480, 2000
    OpenUrlCrossRefPubMed
  20. ↵
    1. Levinsohn EM,
    2. Bryan PJ
    : Computed tomography in unilateral extremity swelling of unusual cause. J Comp Assist Tomogr 3:67–70, 1979
    OpenUrlPubMed
  21. ↵
    1. Grigoriadis E,
    2. Fam AG,
    3. Starok M,
    4. Ang LC
    : Skeletal muscle infarction in dia betes mellitus. J Rheumatol 27:1063–1068, 2000
    OpenUrlPubMedWeb of Science
  22. ↵
    1. Rocca PV,
    2. Alloway JA,
    3. Nashel DJ
    : Diabetic muscular infarction. Semin Arthritis Rheum 22:280–287, 1993
    OpenUrlPubMedWeb of Science
  23. ↵
    1. Delaney-Sathy LO,
    2. Fessell DP,
    3. Jacobson JA,
    4. Hayes CW
    : Sonography of diabetic muscle infarction with MR imaging, CT, and pathologic correlation. AJR Am J Roentgenol 174:165–169, 2000
    OpenUrlPubMed
  24. ↵
    1. Barohn RJ,
    2. Kissel JT
    : Case of the month: painful thigh mass in a young woman: diabetic muscle infarction. Muscle Nerve 15:850–855, 1992.
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
Clinical Diabetes: 31 (2)

In this Issue

April 2013, 31(2)
  • Table of Contents
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Clinical Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Diabetic Myonecrosis: An Indian Experience
(Your Name) has forwarded a page to you from Clinical Diabetes
(Your Name) thought you would like to see this page from the Clinical Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Diabetic Myonecrosis: An Indian Experience
Dayanidhi Meher, Vivek Mathew, Raiz Ahmed Misgar, Satinath Mukherjee, Subhankar Chowdhury, Jyothi Chowdhury
Clinical Diabetes Apr 2013, 31 (2) 53-58; DOI: 10.2337/diaclin.31.2.53

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Diabetic Myonecrosis: An Indian Experience
Dayanidhi Meher, Vivek Mathew, Raiz Ahmed Misgar, Satinath Mukherjee, Subhankar Chowdhury, Jyothi Chowdhury
Clinical Diabetes Apr 2013, 31 (2) 53-58; DOI: 10.2337/diaclin.31.2.53
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • IN BRIEF
    • Case Report 1
    • Case Report 2
    • Case Report 3
    • Case Report 4
    • Case Report 5
    • Case Report 6
    • Overview of Myonecrosis
    • Clinical presentation
    • Pathophysiology of myonecrosis
    • Laboratory investigations and radiology
    • Differential diagnosis
    • Treatment and prognosis
    • Experience with diabetic myonecrosis
    • Conclusion
    • Footnotes
    • REFERENCES
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Comparison of Two Electronic Systems for Obtaining Diabetes Care Indicators in Clinical Practice
  • Focus on the Positive: A Qualitative Study of Positive Experiences Living With Type 1 or Type 2 Diabetes
  • Prevalence of and Characteristics Associated With Overbasalization Among Patients With Type 2 Diabetes Using Basal Insulin: A Cross-Sectional Study
Show more Feature Articles

Similar Articles

Navigate

  • Current Issue
  • Papers in Press
  • Abridged Standards of Care
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Diabetes Care
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Clinical Diabetes Print ISSN: 0891-8929, Online ISSN: 1945-4953.